Lantheus Holdings, Inc. (LNTH)
NASDAQ: LNTH · IEX Real-Time Price · USD
-2.38 (-2.92%)
At close: Jun 21, 2024, 4:00 PM
-0.08 (-0.10%)
After-hours: Jun 21, 2024, 7:35 PM EDT

Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer.

In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;.

It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC.

The company was founded in 1956 and is based in Bedford, Massachusetts.

Lantheus Holdings, Inc.
Lantheus Holdings logo
Country United States
Founded 1956
IPO Date Jun 25, 2015
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 834
CEO Brian A. Markison

Contact Details

331 Treble Cove Road
North Billerica, Massachusetts 01862
United States
Phone 978 671-8001

Stock Details

Ticker Symbol LNTH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001521036
CUSIP Number 516544103
ISIN Number US5165441032
Employer ID 35-2318913
SIC Code 2835

Key Executives

Name Position
Brian A. Markison Chief Executive Officer and Director
Paul M. Blanchfield President
Robert J. Marshall Jr., CFA Chief Financial Officer and Treasurer
Daniel M. Niedzwiecki Chief Administrative Officer, General Counsel and Corporate Secretary
Dr. Jean-Claude Provost M.D. Chief Medical Officer
Andrea Sabens Chief Accounting Officer
Dorothy Barr Senior Vice President of Manufacturing and Technical Operations
Mark Richard Kinarney Senior Director of Investor Relations
Linda S. Lennox Vice President of Corporate Communications and Chief of Staff
Carol Walker Senior Vice President of Quality

Latest SEC Filings

Date Type Title
Jun 13, 2024 144 Filing
May 31, 2024 SD Form - SD
May 31, 2024 144 Filing
May 30, 2024 144 Filing
May 28, 2024 144 Filing
May 28, 2024 144 Filing
May 15, 2024 8-K Current Report
May 13, 2024 144 Filing
May 2, 2024 10-Q Quarterly Report
May 2, 2024 8-K Current Report